Table 3.

Treatment-Emergent Adverse Events in >10% of Patients in the Micafungin Treatment or Standard Care Group (Safety Analysis Set)

Treatment-Emergent Adverse Events	Micafungin (n = 173), No. (%)	Standard Care (n = 172), No. (%)
Abdominal pain	21 (12.1)	15 (8.7)
Diarrhea	19 (11.0)	19 (11.0)
Pleural effusion	26 (15.0)	38 (22.1)
Anemia	20 (11.6)	23 (13.4)
Liver transplant rejection (clinical)	29 (16.8)	14 (8.1)
Pyrexia	16 (9.2)	19 (11.0)
Hypertension	26 (15.0)	18 (10.5)
Cholestasis	12 (6.9)	19 (11.0)